New Study Shows Different Perceptions of Control Among Physicians and Patients May Lead to Suboptimal Type 2 Diabetes Management

PR61801

STOCKHOLM, Sweden, Sept. 15/PRNewswire=KYODO JBN/ --

    Results presented today at the European Association for the Study of

Diabetes (EASD) showed that increased awareness about how patients' and

physicians' perceptions of control differ, could benefit physician-patient

communication and improve diabetes management.[1] New findings from the

Perceptions of Control (POC) study showed adults with type 2 diabetes

uncontrolled on basal insulin had a broader definition of control, perceived

greater obstacles to maintaining control and that life was impacted

significantly more than physicians expected.[1]

    To view the Multimedia News Release, please click:

http://www.multivu.com/players/English/7625651-study-perceptions-type-2-diabetes

    "There is a significant gap in perceptions of control between physicians

and patients in how they define control, the obstacles and how being

uncontrolled on basal insulin impacts patients' daily lives," said Meryl Brod,

PhD, lead investigator of the POC research study. "Having a more open dialogue

during consultations may provide more insight into these critical factors which

could improve diabetes management and lead to more effective individualised

treatment plans."

    The study identified that physicians defined control in measurable,

clinical terms such as frequency/severity of hypoglycaemia (93% vs 69%,

p＜0.001), complications (89% vs 75%, p＜0.001) and HbA1c (85% vs 79%, p＜0.05)

versus patients uncontrolled on basal insulin respectively.[1] Although these

clinical measures were important to people with type 2 diabetes, their

definitions of control had a much broader focus than physicians and included

the amount of insulin (units) taken per day (78% vs 29%, p＜0.001), energy

levels (75% vs 33%, p＜0.001) and how much they have to think about their

disease (68% vs 31%,

p＜0.001) amongst other factors.[1]

    People with type 2 diabetes uncontrolled on basal insulin perceived more

obstacles to achieving control compared to physicians, including stress (75% vs

54%, p＜0.001), medicine side-effects (70% vs 56%, p＜0.001) and a lack of

patient support groups (56% vs 11%, p＜0.001).[1]

    The impact of being uncontrolled on basal insulin and how it interfered in

one's life was perceived as significantly greater than physicians believed

including aspects such as mood/emotions (63% vs 33%, p＜0.001), making plans

(62% vs 16%, p＜0.001) and how much one accomplished during the day (62% vs 23%

p＜0.001) amongst other factors.[1]

    About the Perception of Control (POC) Study

    The POC study was based on information collected from a web survey of 300

physicians and 1,012 adults with type 2 diabetes uncontrolled on basal insulin

(physician-confirmed HbA1c＞ 8% (64 mmol/mol)) from the UK (n=100 physicians and

620 patients), Sweden (n=100 physicians and 240 patients) and Switzerland

(n=100 physicians and 152 patients).[1] Information was also collected from a

control group of 295 adults with type 2 diabetes controlled on basal insulin

(physician-confirmed HbA1c ＜7.5% (59 mmol/mol) from the UK.[1] In total, data

were collected from 1,607 patients and physicians for analysis. The purpose of

the study was to investigate how this patient population perceived control and

whether it differed from perceptions of control among physicians.[1]  

    About Novo Nordisk

    Novo Nordisk is a global healthcare company with more than 90 years of

innovation and leadership in diabetes care. This heritage has given us

experience and capabilities that also enable us to help people defeat other

serious chronic conditions: haemophilia, growth disorders and obesity.

Headquartered in Denmark, Novo Nordisk employs approximately 39,700 people in

75 countries and markets its products in more than 180 countries. For more

information, visit novonordisk.com [http://www.novonordisk.com ], Facebook

[http://www.facebook.com/novonordisk ], Twitter

[http://www.twitter.com/novonordisk ], LinkedIn

[http://www.linkedin.com/company/novo-nordisk ], YouTube

[http://www.Youtube.com/novonordisk ]

    Further Information

    Media:     

    Katrine Sperling

    +45-4442-6718

    krsp@novonordisk.com

    Asa Josefsson

    +45-3079-7708

    aajf@novonordisk.com

    Investors:

    Peter Hugreffe Ankersen

    +45-3075-9085

    phak@novonordisk.com

    Melanie Raouzeos

    +45-3075-3479

    mrz@novonordisk.com

    Daniel Bohsen

    +45-3079-6376

    dabo@novonordisk.com

    Frank Daniel Mersebach (US)

    +1-609-235-8567

    fdni@novonordisk.com

    Reference

    1) Brod M, et al. Perceptions of diabetes control among physicians and

patients with uncontrolled type 2 diabetes using basal insulin. Poster

presentation (#890) at the 51st European Association for the Study of Diabetes

(EASD) Annual Meeting, 16 September 2015.

    SOURCE: Novo Nordisk